Cargando…

Familial Partial Lipodystrophy (FPLD): Recent Insights

Lipodystrophies are a heterogeneous group of congenital or acquired disorders, characterized by partial or generalized loss of adipose tissue. Familial partial lipodystrophy (FPLD) presents with genetic and phenotypic variability with insulin resistance, hypertriglyceridemia and hepatic steatosis be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bagias, Christos, Xiarchou, Angeliki, Bargiota, Alexandra, Tigas, Stelios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7224169/ https://www.ncbi.nlm.nih.gov/pubmed/32440182 http://dx.doi.org/10.2147/DMSO.S206053

Ejemplares similares

Familial partial lipodystrophy and proteinuric renal disease due to a missense c.1045C > T LMNA mutation
por: Fountas, Athanasios, et al.
Publicado: (2017)

Polycystic ovary syndrome in familial partial lipodystrophy type 2 (FPLD2): basic and clinical aspects
por: Gambineri, Alessandra, et al.
Publicado: (2018)

MON-695 Multiple Recurrent Lipomatoses with Thiazolidinedione Therapy in Familial Partial Lipodystrophy, Dunnigan Variety (FPLD2)
por: Patni, Nivedita, et al.
Publicado: (2020)

Peroxisomal proliferator activated receptor-γ deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3)
por: Francis, Gordon A, et al.
Publicado: (2006)

Familial Partial Lipodystrophy—Literature Review and Report of a Novel Variant in PPARG Expanding the Spectrum of Disease-Causing Alterations in FPLD3
por: Rutkowska, Lena, et al.
Publicado: (2022)

SUN-135 Dual Energy X-Ray Absorptiometry (DEXA) as a Diagnostic Tool for Familial Partial Lipodystrophy, Dunnigan Variety (FPLD2)
por: Vasandani, Chandna, et al.
Publicado: (2019)

Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study
por: Foss-Freitas, Maria C., et al.
Publicado: (2021)

Describing the natural history of clinical, biochemical and radiological outcomes of children with familial partial lipodystrophy type 2 (FPLD2) from the United Kingdom: A retrospective case series
por: Zhong, Zhu Xuan, et al.
Publicado: (2022)

Molecular and Mechanobiological Pathways Related to the Physiopathology of FPLD2
por: Varlet, Alice-Anaïs, et al.
Publicado: (2020)

Familial Partial Lipodystrophy: A Case Study and Review of Recent Literature
por: Tipu, Ali, et al.
Publicado: (2021)

SUN-556 Cardiac Phenotype in Familial Partial Lipodystrophy
por: Eldin, Abdelwahab Jalal, et al.
Publicado: (2020)

Evaluation of epicardial adipose tissue in familial partial lipodystrophy
por: Godoy-Matos, Amélio Fernando, et al.
Publicado: (2015)

Bone Mineral Density in Adult Patients with Type 1 Diabetes Mellitus Assessed by Both DXA and QCT
por: Barmpa, Eleftheria, et al.
Publicado: (2023)

Diagnostic Challenge in PLIN1-Associated Familial Partial Lipodystrophy
por: Jéru, Isabelle, et al.
Publicado: (2019)

Targeted Therapeutic Approach in Patients With Familial Partial Lipodystrophy Type 3
por: Cohen, Benjamin, et al.
Publicado: (2021)

Type 2 Diabetes With Partial Lipodystrophy of the Limbs: A new lipodystrophy phenotype
por: Strickland, Leah R., et al.
Publicado: (2013)

Clinical Spectrum of LMNA-Associated Type 2 Familial Partial Lipodystrophy: A Systematic Review
por: Fernandez-Pombo, Antia, et al.
Publicado: (2023)

Cardiac Alterations in Patients with Familial Lipodystrophy
por: Romano, Minna Moreira Dias, et al.
Publicado: (2020)

An Uncommon Association of Familial Partial Lipodystrophy, Dilated Cardiomyopathy, and Conduction System Disease
por: Panikkath, Ragesh, et al.
Publicado: (2016)

Novel Heterozygous LMNA Variants Causing Familial Partial Lipodystrophy, Dunnigan Variety
por: Wadhwa, Akhilesh, et al.
Publicado: (2021)

Phenotypic Differences Among Familial Partial Lipodystrophy Due to LMNA or PPARG Variants
por: Vasandani, Chandna, et al.
Publicado: (2022)

PSUN138 Demonstration of Progressive Beta-Cell Failure in Familial Partial Lipodystrophy
por: De Freitas, Maria Foss, et al.
Publicado: (2022)

Endocrine and metabolic manifestations in inflammatory bowel disease
por: Tigas, Stelios, et al.
Publicado: (2012)

Clinical and imaging evaluation of the response to intravenous steroids in patients with Graves’ orbitopathy and analysis on who requires additional therapy
por: Tsirouki, Theodora, et al.
Publicado: (2016)

Lamin A, Chromatin and FPLD2: Not Just a Peripheral Ménage-à-Trois
por: Briand, Nolwenn, et al.
Publicado: (2018)

Clinical Characteristics, Phenotype of Lipodystrophy and a Genetic Analysis of Six Diabetic Japanese Women with Familial Partial Lipodystrophy in a Diabetic Outpatient Clinic
por: Iwanishi, Masanori, et al.
Publicado: (2018)

Leptin in Relation to the Lipodystrophy-Associated Metabolic Syndrome
por: Mantzoros, Christos S.
Publicado: (2012)

Evaluation of the hypothalamic–pituitary–adrenal axis in a case series of familial partial lipodystrophy
por: Elias, Cecília Pacheco, et al.
Publicado: (2019)

SUN-057 Familial Partial Lipodystrophy Presenting As Recurrent Acute Pancreatitis- Challenges In Management
por: Aljariri Alhesan, Nour, et al.
Publicado: (2019)

Massive labial lipomatous hypertrophy in familial partial lipodystrophy seen on computed tomographic angiography
por: Selting, Kevin, et al.
Publicado: (2019)

2287 ECG and echo characteristics in familial partial lipodystrophy: The impact of Lamin A variants
por: Eldin, Abdelwahab J., et al.
Publicado: (2018)

Challenges in Managing Metabolic Complications in a Patient With Familial Partial Lipodystrophy Type 3
por: Shah, Kajal, et al.
Publicado: (2021)

Metabolic Improvements After Gastric Sleeve Surgery in a Patient With Familial Partial Lipodystrophy
por: Niaz, Azra, et al.
Publicado: (2021)

SAT676 Severe Recurrent Pancreatitis In A Familial Partial Lipodystrophy Patient On Metreleptin
por: Sargin, Pinar, et al.
Publicado: (2023)

Familial Partial Lipodystrophy: Clinical Features, Genetics and Treatment in a Greek Referral Center
por: Kountouri, Aikaterini, et al.
Publicado: (2023)

Recent advances in understanding lipodystrophy: a focus on lipodystrophy-associated cardiovascular disease and potential effects of leptin therapy on cardiovascular function
por: Bruder-Nascimento, Thiago, et al.
Publicado: (2019)

Rapid response to leptin therapy in a FPLD patient with a novel PPARG missense variant
por: Melzer, Fiona, et al.
Publicado: (2021)

MON-104 Defining the Contribution of Weight to the Extent of Metabolic Disease in FPLD: Insights from a Retrospective "Matched" Case-Control Study
por: Koo, Eden, et al.
Publicado: (2019)

Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges
por: Chiquette, Elaine, et al.
Publicado: (2017)

Effects of Hypoglycemia on Cardiovascular Function in Patients with Diabetes
por: Christou, Maria A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pigb2v45m43054ol1uu7uns3cj